Kintor Pharmaceutical Ltd

Detailed Description

Kintor Pharmaceutical Limited, a biopharmaceutical company, engages in the research and development of drugs for the treatment of various cancers and other androgen receptor (AR) - related diseases in China, the United States, and Taiwan. The company's lead drug candidates include Proxalutamide, a small molecule second generation AR antagonist that is in various clinical trials for metastatic castration-resistant prostate cancer and breast cancer, as well as for the treatment of COVID-19; and Pyrilutamide, which is in various clinical trials for androgenetic alopecia and acne vulgaris. It also develops ALK-1 for the treatment of metastatic hepatocellular carcinoma and liver cancer; Detorsertib, a second-generation mTOR inhibitor for the treatment of metastatic solid tumours; GT1708F for the treatment of leukaemia and basal-cell carcinoma; and GT20029 for the treatment of androgenetic alopecia and acne vulgaris. The company was founded in 2009 and is headquartered in Suzhou, China.